Literature DB >> 21762116

A broad symmetry criterion for nonparametric validity of parametrically based tests in randomized trials.

Russell T Shinohara1, Constantine E Frangakis, Constantine G Lyketsos.   

Abstract

Pilot phases of a randomized clinical trial often suggest that a parametric model may be an accurate description of the trial's longitudinal trajectories. However, parametric models are often not used for fear that they may invalidate tests of null hypotheses of equality between the experimental groups. Existing work has shown that when, for some types of data, certain parametric models are used, the validity for testing the null is preserved even if the parametric models are incorrect. Here, we provide a broader and easier to check characterization of parametric models that can be used to (i) preserve nonparametric validity of testing the null hypothesis, i.e., even when the models are incorrect, and (ii) increase power compared to the non- or semiparametric bounds when the models are close to correct. We demonstrate our results in a clinical trial of depression in Alzheimer's patients.
© 2011, The International Biometric Society.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21762116      PMCID: PMC3909656          DOI: 10.1111/j.1541-0420.2011.01642.x

Source DB:  PubMed          Journal:  Biometrics        ISSN: 0006-341X            Impact factor:   2.571


  7 in total

1.  Addressing an idiosyncrasy in estimating survival curves using double sampling in the presence of self-selected right censoring.

Authors:  C E Frangakis; D B Rubin
Journal:  Biometrics       Date:  2001-06       Impact factor: 2.571

2.  Super learner.

Authors:  Mark J van der Laan; Eric C Polley; Alan E Hubbard
Journal:  Stat Appl Genet Mol Biol       Date:  2007-09-16

3.  Cornell Scale for Depression in Dementia.

Authors:  G S Alexopoulos; R C Abrams; R C Young; C A Shamoian
Journal:  Biol Psychiatry       Date:  1988-02-01       Impact factor: 13.382

4.  A twelve-week, double-blind, randomized comparison of nortriptyline and paroxetine in older depressed inpatients and outpatients.

Authors:  B H Mulsant; B G Pollock; R Nebes; M D Miller; R A Sweet; J Stack; P R Houck; S Bensasi; S Mazumdar; C F Reynolds
Journal:  Am J Geriatr Psychiatry       Date:  2001       Impact factor: 4.105

5.  Treating depression in Alzheimer disease: efficacy and safety of sertraline therapy, and the benefits of depression reduction: the DIADS.

Authors:  Constantine G Lyketsos; Lourdes DelCampo; Martin Steinberg; Quincy Miles; Cynthia D Steele; Cynthia Munro; Alva S Baker; Jeannie-Marie E Sheppard; Constantine Frangakis; Jason Brandt; Peter V Rabins
Journal:  Arch Gen Psychiatry       Date:  2003-07

6.  Covariate adjustment for two-sample treatment comparisons in randomized clinical trials: a principled yet flexible approach.

Authors:  Anastasios A Tsiatis; Marie Davidian; Min Zhang; Xiaomin Lu
Journal:  Stat Med       Date:  2008-10-15       Impact factor: 2.373

7.  Using regression models to analyze randomized trials: asymptotically valid hypothesis tests despite incorrectly specified models.

Authors:  Michael Rosenblum; Mark J van der Laan
Journal:  Biometrics       Date:  2009-02-04       Impact factor: 2.571

  7 in total
  1 in total

1.  Estimation of treatment effects in matched-pair cluster randomized trials by calibrating covariate imbalance between clusters.

Authors:  Zhenke Wu; Constantine E Frangakis; Thomas A Louis; Daniel O Scharfstein
Journal:  Biometrics       Date:  2014-08-27       Impact factor: 2.571

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.